First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors - Abdul Razak, A R; Mau-Soerensen, M; Gabrail, N Y (J Clin Oncol, 2016)
, et al.